J Cancer 2022; 13(15):3615-3622. doi:10.7150/jca.67569 This issue Cite

Research Paper

Bcl-6-dependent risk stratification by nuclear expression of Peli1 in diffuse large B-cell lymphoma

Ki Rim Lee1,2, Jeong-Ok Lee3,4, Jong Seok Lee3,4, Jin Ho Paik1,2✉

1. Department of Pathology, Seoul National University Bundang Hospital, Seongnam, South Korea
2. Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea
3. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
4. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea

Citation:
Lee KR, Lee JO, Lee JS, Paik JH. Bcl-6-dependent risk stratification by nuclear expression of Peli1 in diffuse large B-cell lymphoma. J Cancer 2022; 13(15):3615-3622. doi:10.7150/jca.67569. https://www.jcancer.org/v13p3615.htm
Other styles

File import instruction

Abstract

Graphic abstract

Background/Aim: Peli1 is an E3 ubiquitin ligase involving lymphomagenesis by lysine 63 ubiquitination-mediated stabilization of Bcl-6 with in diffuse large B-cell lymphoma (DLBCL).

Materials and Methods: We categorized nuclear expression of Peli1 according to Bcl-6 status by immunohistochemistry in DLBCL (n=100), and analyzed clinicopathologic association with prognosis.

Results: We established Bcl-6/Peli1 risk model composed of high risk (Bcl-6+/Peli1+ or Bcl-6-/Peli1-; n=64) and low risk (Bcl-6+/Peli1- or Bcl-6-/Peli1+; n=36). High risk group had more frequent non-GCB subtype (83% vs 64%; p=0.033) and Bcl-6-negativity (69% vs 28%; p<0.001) than low risk group. Univariate survival analysis for progression-free survival (PFS) and overall survival (OS) revealed Bcl-6/Peli1 risk group (p=0.026 and p=0.021) and other conventional variables including international prognostic index (IPI), stage, ECOG performance status, number of extranodal sites were significant prognostic factors, along with B symptoms for OS. In multivariate analysis for PFS, Bcl-6/Peli1 risk group (p=0.032; HR=3.29), IPI (p=0.013; HR=3.39) and ECOG PS (p=0.035; HR=3.08) were independent prognostic factors. In multivariate analysis for OS, Bcl-6/Peli1 risk group (p=0.048; HR=7.87) and IPI (p=0.001; HR=12.15) were associated with prognosis.

Conclusions: DLBCL had distinctive risk groups according to pairs of nuclear Peli1 and Bcl-6 expression. These results suggest the potential role of Peli1 and Bcl-6 in risk assessment in DLBCL.

Keywords: malignant lymphoma, diffuse large B-cell lymphoma, Bcl-6, Peli1


Citation styles

APA
Lee, K.R., Lee, J.O., Lee, J.S., Paik, J.H. (2022). Bcl-6-dependent risk stratification by nuclear expression of Peli1 in diffuse large B-cell lymphoma. Journal of Cancer, 13(15), 3615-3622. https://doi.org/10.7150/jca.67569.

ACS
Lee, K.R.; Lee, J.O.; Lee, J.S.; Paik, J.H. Bcl-6-dependent risk stratification by nuclear expression of Peli1 in diffuse large B-cell lymphoma. J. Cancer 2022, 13 (15), 3615-3622. DOI: 10.7150/jca.67569.

NLM
Lee KR, Lee JO, Lee JS, Paik JH. Bcl-6-dependent risk stratification by nuclear expression of Peli1 in diffuse large B-cell lymphoma. J Cancer 2022; 13(15):3615-3622. doi:10.7150/jca.67569. https://www.jcancer.org/v13p3615.htm

CSE
Lee KR, Lee JO, Lee JS, Paik JH. 2022. Bcl-6-dependent risk stratification by nuclear expression of Peli1 in diffuse large B-cell lymphoma. J Cancer. 13(15):3615-3622.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.